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ABSTARCT
Methods: A prospective observational study for a period of 6 months was conducted in the pediatrics department of RVM hospital. Outpatients under 
the age of 14 years given antibiotics for the treatment of URTI were included in the study. A total of 99 study subjects were included in the study, 
divided into three groups each containing 33 sample sizes (clarithromycin, cefuroxime, and levofloxacin). Patient data was collected using a form and 
verbal consent was obtained from patients/patient representatives, and drugs were given using the lottery method. Follow-up was done and noted 
for the 3rd, 5th, 7th day through telephonic calls, and the collected data were evaluated using statistical analysis.
Results: Pool data from 99 patients shows that many patients belong to 0–5 years age groups (age distribution), and males were more than female 
(gender distribution). Clarithromycin (cure rate 3 days) and cefuroxime (cure rate 5 days) showed an equal rate of cure percentage (94%), while 
levofloxacin for 3–5 days with a 3% failure rate. A significant difference of p<0.05 (p=0.000) was observed and no adverse events were noted.
Conclusion: The study findings showed, out of 3 drugs, clarithromycin and cefuroxime showed an equal efficacy rate of 94%, but clarithromycin 
showed shorter duration of outcome, i.e., 3 days. Hence, clarithromycin is effective than the other two drugs in the treatment of URTI.
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INTRODUCTION
The respiratory tract is much more vulnerable to infection than other 
body parts since bacteria or viruses can easily enter the tract when a 
person breathes in [1]. The upper respiratory tract infections (URTI) 
include epiglottis, otitis media, laryngitis, pharyngitis, acute rhinitis, 
laryngotracheitis, influenza, tonsillitis, and acute rhinosinusitis [2].
URTI is a frequent major morbid condition among pediatrics. Acute 
pharyngitis constitutes 1 percent of all admissions to the outpatient 
hospital, and predominantly seen in 4–7–year–old patients [3]. The 
incidence of epiglottis has significantly decreased. Pertussis has an 
estimated occurrence of 48.5 million cases worldwide and causes about 
295,000 deaths per annum. In low-income countries, the infant mortality 
rate is found at about 4%. The increased level may affect children in more 
percentages, but hormonal effects may also affect nasal mucosa [4].
Majority of hospital visits in children are caused by infection, therefore, 
children are prescribed a variety of antibiotics. One of the reasons children 
are particularly vulnerable to respiratory infections is that they breathe 
more rapidly than adults and so absorb more pollutants. Physicians are 
frequently challenged by antimicrobial resistance (AMR) associated 
with community-acquired respiratory tract infections. According to the 
World Health Organization (WHO), 600,000 children died in 2016 from 
acute lower respiratory infections caused by polluted air. The rate of 
occurrence of adverse drug reaction (ADR) is also very high in pediatrics 
compared to adults. Approximately 58,000 infants died in 2013 in India 
due to antibiotics failing to save them from infections [5,6].
Antibiotics are of the commonly prescribed drugs in hospitals, 
particularly in pediatric wards. AMR results from widespread irrational 
use of antimicrobials, despite the emergence and extraordinary 
advances in medical technology. AMR results from altered susceptibility 
in organisms due to their widespread irrational use. Recent years 
have seen a surge in incidents of AMR, and they are receiving global 
attention. In spite of the fact that AMR is a result of many factors, one 
of the most significant causes is antibiotic indiscrimination. Infections 
were the most common clinical approach, making India one of the most 
leading consumers of antimicrobials in the world [7].
Amoxicillin clavulanate is the 1st-line drug in treating URTI, but frequent 
use of any antibiotic leads the way to resistance and failure of treatment [8]. 
Hence, in this period of increasing AMR, it is essential to have an efficient 
and safe alternative drug along with first-line agents. With a quest to select 
a better alternative, we took antibiotics from each major class of antibiotics, 
i.e., cefuroxime from cephalosporins, clarithromycin from macrolides, and 
levofloxacin from fluoroquinolones. The current study is designed to elicit 
and correlate the effects of cefuroxime, clarithromycin, and levofloxacin.
METHODS
Study site and duration
The investigation was done in pediatrics outpatient care of 800 
bedded RVM institutes of medical sciences and research center, a 
tertiary care hospital located in Lakshmakkapally, Medak District, 
Telangana. The study duration was 6 months between October 2020 
and March 2020.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i10.42957. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
Research Article
Objective: The upper respiratory infections cause considerable morbidity mainly in children due to the fact that they mainly affect 
children. Accordingly, a study was conducted on antibiotics to compare the effectiveness of clarithromycin, cefuroxime, and levofloxacin for 
treating upper respiratory tract infections (URTI) in children.
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Study design
A prospective, interventional, randomized double-blind, observational 
study was conducted among subjects with URTI attending the 
outpatient pediatric department of RVM hospital. The three antibiotics 
(cefuroxime, clarithromycin, and levofloxacin) commonly prescribed 
for URTI were assessed and compared for their therapeutic efficacy. 
The strength doses (15 mg/kg/7 days) and duration of treatment of 
the three antibiotics were given as per the WHO model formulary for 
children and Model List of Essential Medicines 2019 to ensure that 
given drug in prescribed dose is safe in children [9,10].
A. Clarithromycin syrup – CLARINOVA – 125 mg/5 ml
B. Cefuroxime syrup - CEFAKIND – 125 mg/5 ml
C.	 Levofloxacin	syrup	–	L-CIN	–	125	mg/5	ml.
The physician was kept unaware of the codes given to each antibiotic 
to ensure blinding. When a subject meets inclusion criteria approaches 
the outpatient department, the prescriber selected a chit written with 
the code A, B, or C by lottery method. The pharmacist was requested 
to dispense antibiotics as mentioned above upon receiving the study 
prescriptions. The study was initially approved by the institutional 
ethical committee (code: GCPK/IEC/JUNE2019-20/B04) and consent 
was obtained from the study subjects (parents/guardians) before the 
study. They were explained about the telephonic follow-up before the 
study (Fig. 1).
Inclusion and exclusion criteria
Outpatients	 ≤14	 years	 with	 diagnosed	 with	 URTI	 in	 the	 pediatric	
department of RVM hospital were included in the study. Patients other 
than URTI, >14 years and inpatients of pediatric department of RVM 
hospital were excluded from the study.
Sample size and data collection
A total of 99 sample size was collected having 33 samples in each 
category of antibiotics. Before including in the study, a written informed 
was taken from study subjects. During the 6 months of study, relevant 
information was collected from the patient representative, by asking 
questionnaires including chief complaints, past/present medication 
history, etc., and entered into pre-designed data collection forms. 
Follow-up regarding alleviation of symptoms, ADR, if any, and adherence 
was done through telephonic interview starting at 3rd day followed by 
5th and 7th day based on necessity and till symptoms subside.
Classification of outcomes
The outcomes of the study subjects were classified as:
Cured
If, patient is completely relieved from symptoms by the treatment.
Improved
If, the patient’s condition is better than before by the treatment.
Failed
If, the patient’s situation is deteriorated or no betterment is observed 
by the treatment.
Statistical analysis
Descriptive statistics and graphical presentation of data analysis 
were shown as frequency, percentage, mean, and SD. Comparisons of 
categorical data between groups were done using Pearson χ2 analysis, 
Kruskal Wallis Test, and 1-way analysis of variance (ANOVA). Statistical 
analysis, using SPSS statistical software, version 22, was performed. 
RESULTS
Out of 99 patients, the patient’s near age was noticed to be 
4.92±3.65 years with average weight of 13.9± 12.0 kg. Most patients 
fall under the peer group of 0–5 years (68%). Out of 99 patients, 52 are 
male and 47 are female (Table 1).
On the telephonic interview, the treatment outcomes were observed 
and the effects of three drugs were compared. A χ2-test was applied 
to check the homogeneity of the attributes in respect of a particular 
characteristic. The results showed that clarithromycin and cefuroxime 
appeared effective than levofloxacin. Among 33 subjects received 
levofloxacin, 52% of subjects reported complete cure, 45% improved 
their clinical symptoms, while 3% reported no improvement upon 
antibiotic treatment (Table 2 and Fig. 2).
The findings of duration of treatment outcomes showed that majority 
of subjects receiving clarithromycin (73%) showed improvement in 
their symptoms within three days while it was 5 days for cefuroxime 
(73%) and 7 days for levofloxacin (58%). One way ANOVA is 
performed to correlate the effects of the drugs by the period of 
outcome, i.e., 3 days/5 days/7 days (parametric) and was found that 
clarithromycin has shown more efficacy within less duration i.e., 3 days 
(Table 3 and Fig. 3).
DISCUSSION
Among 99 pediatric study subjects, the prevalence of URTI is high in 
0–5 year’s age group may be due to low immunity. On the telephonic 
follow-up of patients, we checked on the compliance of subjects and 
established that patients in all drug groups were adherent to every 
medication prescribed to them. So failure to receive medication was not 
a factor for the efficacy shown by the test drugs. No ADR was reported 
Table 1: Age, gender, and body weight‑wise distribution of the 
study population
Parameter Frequency (n=99) Total (%)
Drug A Drug B Drug C
Age
0–5 years 27 24 16 67 (68)
6–10 years 3 7 12 22 (22)
11–14 years 3 2 5 10 (10)
Total 33 33 33
Mean±SD 3.7±3.5 4.7±3.1 6.3±3.8 4.92±3.65
IQR 0.2–13 0.2–14 0.6–13
Gender
Male 19 15 18 52 (53)
Female 14 18 15 47 (47)
Average weight 10.9±10.1 15.1±13.9 12.5±10.9 13.9±12.0
Table 2: Comparison of treatment outcomes of three antibiotics 
given for URTI in paediatrics
Drugs Outcome (χ2, p<0.05)
Cured Improved Failure
Drug A 31 (94) 2 (6) 0 (22.43, 0.0000*)
Drug B 31 (94) 2 (6) 0
Drug C 17 (52) 15 (45) 1 (3)
Total 79 19 1
*p<0.05 is a significant relation b/w Drugs and Outcome by using χ2-test,  
URTI: Upper respiratory tract infections
Table 3: Comparison of duration of treatment outcomes of three 
antibiotics given for URTI in paediatrics
Drugs Duration of outcome in days n (%) (F, p<0.05)
3 Days 5 Days 7 Days Mean±SD
Drug A 24 (73) 6 (18) 3 (9) 3.73±1.31 (24.87, 0.0000)
Drug B 7 (21) 24 (73) 2 (6) 4.70±1.02*
Drug C 4 (12) 10 (30) 19 (58) 5.91±1.42*
Total 35 40 24
*p<0.05; Duration of Outcome mean values are statistically noticeable between 
drugs by using one-way ANOVA, URTI: Upper respiratory tract infections
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by the patient’s caregivers upon telephonic inquiry. However, it does 
not mean that there won’t be any ADR with the test drugs.
Among the clarithromycin, cefuroxime and levofloxacin groups, 
clarithromycin and cefuroxime have shown a 94% cure rate whereas 
levofloxacin showed 52% cure rate. Collating with the study conducted 
by Siepman in the year, 1998, it was found that these 2 drugs were 
equally efficacious [11]. A study by Guay et al., expressed that 
clarithromycin has high effects than cefuroxime. Another study by 
Henry concluded that cefuroxime (250 mg, twice daily) is as potent as 
amoxicillin (500 mg, TID) that provide baseline data for the utility of 
these selected antibiotics in URTI [11,12].
A study by AdelGlass et al., in contrast to the above results, concluded that 
levofloxacin and clarithromycin showed equal efficacy but the standards 
of life for levofloxacin are higher  [13]. In a randomized comparative 
study of levofloxacin versus amoxicillin/clavulanate for treatment of 
pediatrics reported cure rates of 72.4% in levofloxacin-treated and 
69.9% (472 of 675) in amoxicillin/clavulanate-treated children [14]. 
In a similar study of comparison of the efficacy of clarithromycin, 
levofloxacin, and cefuroxime among adults infected with bronchitis 
reported, clinical cure rate of 87.9% with clarithromycin, 87.4% with 
levofloxacin, and 79.8% of those treated with cefuroxime [15].
In this study, the failure with the medication was seen in the Levofloxacin 
group only (3%). This may be because of variability between subjects 
and various factors that could not be studied here. Clarithromycin has 
shown cure before completing three days in 73% of individuals whereas 
cefuroxime has shown 73% within 5 days. Moreover, 50% of them were 
healed between 3 and 5 days of treatment. The time of treatment is 
longer in the levofloxacin group, most patients took more than 5 days 
for improvement in symptoms.
Antibiotic resistance has made infections more difficult to treat today, 
leading to life-threatening situations. Despite this, there are numerous 
encouraging research opportunities in antibiotic use, particularly in 
children. In the global context, antibiotic usage, awareness, knowledge, 
and practice need to be understood. As reported by the WHO, India is 
among the countries with a high rate of drug resistance coupled with 
the irrational use of antimicrobial agents. Despite developing research 
on antimicrobial stewardship, the country is primarily interested in 
drug discovery and development [16,17].
CONCLUSION
By considering our study conducted on 99 patients, we conclude that 
all three drugs are not equally efficacious in treating URTI in pediatric 
patients. Amidst three antibiotics, clarithromycin is more preferable. 
The study can be repeated in a larger sample size to increase reliability. 
As our study is conducted with limited resources, the study can be 
strengthened by culture sensitivity data and patient compliance 
was 100% and no side effects were observed. However, it cannot be 
extrapolated to the bigger sample or population. So advance research 
in some more populations can be held to know safety with these 
antibiotics in pediatric population.
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